Clinical Trials Browser

INDUSTRY × talazoparib × 1 year × Clear all

NCT03395197 2026-04-22

TALAPRO-2

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3 Active not recruiting

Ovarian Neoplasms

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04991480 2026-01-27

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Phase 1 Completed

Breast Neoplasms, Neoplasm Metastasis

NCT04982848 2025-11-18

Korea Post Marketing Surveillance (PMS) Study of Talzenna®

Not yet recruiting

Breast Neoplasms

NCT04497116 2025-10-21

TRESR

Phase 1/2 Completed

276 enrolled 33 charts

Other solid neoplasm

Advanced Solid Tumor

NCT03901469 2025-10-07

TNBC

Phase 2 Terminated

115 enrolled 31 charts

Breast Neoplasms, Triple Negative Breast Neoplasms